Blue Water Vaccines, Inc.

Blue Water Vaccines, Inc., a biotechnology company, engages in the research and development of vaccines to prevent infectious diseases worldwide. The company's lead vaccine programs that are under preclinical development include BWV-101, an influenza vaccine; and BWV-102, a H1 pre-pandemic vaccine. It also has other pipeline under preclinical development comprising BWV-201, a streptococcus pneumoniae induced acute otitis media vaccine program; BWV-301, a norovirus-rotavirus vaccine program; and BWV-302, a norovirus-malaria vaccine program. The company was incorporated in 2018 and is based in Cincinnati, Ohio.

Blue Water Vaccines, Inc. trades as BWV on NASDAQ. The company is classified in Healthcare / Biotechnology and reports in USD.

The current profile places the business in Biotechnology. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $815,371 of revenue and -$14.03M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Blue Water Vaccines, Inc. can be compared against peers such as Affimed N.V., AzurRx BioPharma, Inc., Atreca, Inc., Gritstone bio, Inc., Idera Pharmaceuticals, Inc., Lisata Therapeutics, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $3.41M, beta of 0.00, and return on equity of -89.0%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

BWV currently shows total debt of $48,774 and beta of 0.00. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: 8-K (2026-05-19 00:00:00), 8-K (2026-05-14 00:00:00), 10-Q (2026-05-13 00:00:00), EFFECT (2026-05-11 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.bluewatervaccines.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.